2nd RSC Symposium on Chemical Biology for Drug Discovery
March 20, 2012 - GlaxoSmithKline
GlaxoSmithKline presented on the opportunities and the challenges of drug discovery demand services on March 20, 2012. Within their slides, GSK proposes an increasingly more collaborative approach to filling the gaps in disconnected research by depositing their data on compounds and kinase inhibitors into the public domain under the "GSK Published Kinase Inhibitor Set." The formation of this PKIS specifically emphasizes the importance of Nanosyn's contribution in understanding and defining this set of inhibitors. More so, the discussion around the slides highlights the significance in the precision of micro-fluidics activity-based assays utilized by Nanosyn. The analysis on the high level of quality inthe data within the presentation is paramount to the industry's ever developing and adapting future.